"Retina-Vitreous Surgeons of Central New York's Liverpool Syracuse main office is a regional and national leader in the management of retinal disorders. The physicians are board-certified, fellowship-trained retinal physicians and surgeons, with immense training, knowledge, and experience in diagnosing and treating retinal diseases. RVS is one of New York’s most sophisticated practices devoted to diagnosing and treating vitreoretinal diseases. We limit our practice to disorders of the retina and vitreous. Examples include macular degeneration, diabetic retinopathy, retinal artery and vein occlusions, retinal tears and detachment, ocular trauma, uveitis, inherited retinal diseases retinopathy of prematurity, and intraocular tumors."

During the past decade, Retina-Vitreous Surgeons of Central New York, PC conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 14 clinical trials were completed, i.e. on average, 51.9% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 9 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina-Vitreous Surgeons of Central New York, PC" #1 sponsor was "Jaeb Center for Health Research" with 16 trials, followed by "Hoffmann-La Roche" with 12 trials sponsored, "Kodiak Sciences Inc" with 3 trials sponsored, "ThromboGenics" with 3 trials sponsored and "Oxurion" with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina-Vitreous Surgeons of Central New York, PC" #1 collaborator was "National Eye Institute (NEI)" with 15 trials as a collaborator, "National Institutes of Health (NIH)" with 6 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "Regeneron Pharmaceuticals" with 4 trials as a collaborator and "Allergan" with 3 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Retina-Vitreous Surgeons of Central New York, PC" are "Diabetic Macular Edema" (16 trials), "Diabetic Retinopathy" (10 trials), "Macular Edema" (4 trials), "Proliferative Diabetic Retinopathy" (4 trials) and "Geographic Atrophy" (3 trials). Many other conditions were trialed in "Retina-Vitreous Surgeons of Central New York, PC" in a lesser frequency.

Most popular intervention types in "Retina-Vitreous Surgeons of Central New York, PC" are "Drug" (37 trials), "Procedure" (11 trials), "Other" (9 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (9 trials), "Sham Procedure" (9 trials), "Faricimab" (6 trials), "Placebo" (5 trials) and "KSI-301" (3 trials). Other intervention names were less common.

The vast majority of trials in "Retina-Vitreous Surgeons of Central New York, PC" are 42 trials for "All" genders.

Currently, there are NaN active trials in "Retina-Vitreous Surgeons of Central New York, PC". undefined are not yet recruiting, 4 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Retina-Vitreous Surgeons of Central New York, PC, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Retina-Vitreous Surgeons of Central New York, PC, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".